Talking to patients about Lenacapavir (Sunlenca); the new long-acting injectable medication for HIV

In this episode, Dr. Steven Fine, an infectious disease specialist affiliated with the University of Rochester and Anthony Jordan Health Center explains the pros and cons behind the newly approved Lenacapavir (Sunlenca) injectable for HIV. Dr. Fine receives a lot of questions about the medication in his practice. Many patients have heard good things about the new treatment for HIV that is given as a subcutaneous injection once every 6 months. Dr. Fine discusses the current indication in combination with other agents for “treatment-experienced” HIV patients and possible future uses. You’ll hear about Lenacapavir, the data that led to approval, and how it may be used in the future - including possibly for Pre-Exposure Prophylaxis (PrEP). Related Content: The Capella Trial for Lenocapavir CROI 2023 FDA Approves New HIV Drug for Adults with Limited Treatment Options CEI toll free line for NYS providers: 866-637-2342 Visit us at https://ceitraining.org/